OCEANIC-STROKE: Asundexian Not Linked to More Major Bleeding

This secondary analysis of the OCEANIC-STROKE trial characterized bleeding outcomes in patients with noncardioembolic ischemic stroke or high-risk TIA who received asundexian plus antiplatelet therapy versus placebo. The trial reported no significant increase in major, major or clinically relevant nonmajor, or any bleeding with asundexian, with consistent treatment effects across prespecified subgroups; however, lower gastrointestinal bleeding, primarily rectal bleeding, was more frequent with asundexian (1.7% vs 1.0%).

Most relevant for: Patients with noncardioembolic ischemic stroke or high-risk TIA receiving antiplatelet therapy, including those on planned dual antiplatelet regimens.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.